KaydedilenlerDerginizi ekleyin

Dergiler / Anatolian Current Medical Journal / 2026 / Volume: 8 Issue: 5

Association of prolactin with cardiometabolic risk markers in women with polycystic ovary syndrome: a phenotype-based analysis

Hatice Çalışkan Burgucu(SBÜ Konya Şehir Hastanesi)0000-0001-7699-4580
Emel Yılmaz Kaya(Konya Şehir Hastanesi)0000-0003-1401-6102
Ayşen Yümlü(Konya Şehir Hastanesi)0009-0009-3798-0675
Mehmet Korkmaz(Gürün Devlet Hastanesi)0009-0004-8188-2865
Melike Geyik Bayman(SBÜ Konya Şehir Hastanesi)0000-0003-0008-2205
Oğuzhan Aksu(SBÜ Konya Şehir Hastanesi)0000-0003-4666-7129
Sayfa
—
Yayın Tarihi
2026-09-11
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Among the evaluated cardiometabolic surrogate markers, LAP and SPISE showed the highest discriminatory performance and may provide additional information for cardiometabolic risk assessment in women with PCOS.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aims: Polycystic ovary syndrome (PCOS) is associated with significant metabolic and cardiometabolic abnormalities.
📊
Temel Bulgular & Veri:Methods: A retrospective cohort of 206 women, including 126 with PCOS and 80 controls, was analyzed.
💡
Sonuç & Katkı:Among the evaluated cardiometabolic surrogate markers, LAP and SPISE showed the highest discriminatory performance and may provide additional information for cardiometabolic risk assessment in women with PCOS.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Polycystic ovary syndrome · prolactin · cardiometabolic risk

Abstract

Aims: Polycystic ovary syndrome (PCOS) is associated with significant metabolic and cardiometabolic abnormalities. This study aimed to evaluate prolactin levels and cardiometabolic surrogate indices across PCOS phenotypes and to examine the relationship between prolactin and cardiometabolic parameters in women with PCOS. Methods: A retrospective cohort of 206 women, including 126 with PCOS and 80 controls, was analyzed. Women with PCOS were classified into four phenotypes (A-D). Demographic, anthropometric, metabolic, hormonal, and cardiometabolic variables were assessed. Correlation analysis, logistic regression, and receiver operating characteristic (ROC) curve analysis were performed. Results: Compared with controls, women with PCOS had higher body weight, body-mass index (BMI), waist circumference (WC), triglyceride (TG) levels, insulin resistance-related parameters, triglyceride-glucose (TyG) Index, lipid accumulation product (LAP), and Atherogenic Index of Plasma (AIP), whereas high-density lipoprotein cholesterol (HDL-C) and single point insulin sensitivity estimator (SPISE) values were lower (all p<0.01). Prolactin levels were similar between groups (p=0.182) and across phenotypes. In the PCOS group, prolactin was negatively correlated with BMI, WC, homeostasis model assessment of insulin resistance (HOMA-IR), TyG, LAP, and AIP, and positively correlated with SPISE (all p<0.05). After adjustment for age and BMI, prolactin remained significantly associated with PCOS status. Among the evaluated cardiometabolic indices, LAP showed the highest discriminatory performance (AUC=0.784), followed by SPISE (AUC=0.769). Conclusion: Women with PCOS exhibited adverse metabolic and cardiometabolic profiles. Among the evaluated cardiometabolic surrogate markers, LAP and SPISE showed the highest discriminatory performance and may provide additional information for cardiometabolic risk assessment in women with PCOS.

🔖

Bu Makaleye Atıf Yap

Burgucu, H. Ç., Kaya, E. Y., Yümlü, A., Korkmaz, M., Bayman, M. G., Aksu, O. (2026). Association of prolactin with cardiometabolic risk markers in women with polycystic ovary syndrome: a phenotype-based analysis. Anatolian Current Medical Journal, Volume: 8 Issue: 5. https://doi.org/10.38053/acmj.1974306

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (32)

  1. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6-15. doi:10.1016/j.fertnstert.2016.05.003
  2. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469. doi:10.1210/clinem/dgad463
  3. Sachdeva G, Gainder S, Suri V, Sachdeva N, Chopra S. Comparison of the different PCOS phenotypes based on clinical metabolic, and hormonal profile, and their response to clomiphene. Indian J Endocrinol Metab. 2019;23(3):326-331. doi:10.4103/ijem.IJEM_30_19
  4. Ma YC, Law KS, Wang WS, Chang HM. Phenotypic variations in polycystic ovary syndrome: metabolic risks and emerging biomarkers. J Endocrinol. 2025;267(1):e250226. doi:10.1530/JOE-25-0226
  5. Teede HJ, Khomami MB, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407(10545):2329-2339. doi:10.1016/S0140-6736(26)00717-8
  6. Glintborg D, Altinok M, Mumm H, Buch K, Ravn P, Andersen M. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome. Hum Reprod. 2014;29(8):1773-1779. doi:10.1093/humrep/deu133
  7. Macotela Y, Ruiz-Herrera X, Vázquez-Carrillo DI, Ramírez-Hernandez G, Martínez de la Escalera G, Clapp C. The beneficial metabolic actions of prolactin. Front Endocrinol (Lausanne). 2022;13:1001703. doi:10.3389/fendo.2022.1001703
  8. Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95(7):3347-3351. doi:10.1210/jc.2010-0288
  9. Dobiásová M. AIP-Atherogenic Index of Plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek. 2006;52(1):64-71.
  10. Paulmichl K, Hatunic M, Højlund K, et al. Modification and validation of the triglyceride-to-HDL cholesterol ratio as a surrogate of insulin sensitivity in white juveniles and adults without diabetes mellitus: the single point insulin sensitivity estimator (SPISE). Clin Chem. 2016; 62(9):1211-1219. doi:10.1373/clinchem.2016.257436
  11. Wu TT, Gao Y, Zheng YY, Ma YT, Xie X. Atherogenic Index of Plasma (AIP): a novel predictive indicator for the coronary artery disease in postmenopausal women. Lipids Health Dis. 2018;17(1):197. doi:10.1186/s12944-018-0828-z
  12. Ahn N, Baumeister SE, Amann U, et al. Visceral Adiposity Index (VAI), lipid accumulation product (LAP), and product of triglycerides and glucose (TyG) to discriminate prediabetes and diabetes. Sci Rep. 2019; 9(1):9693. doi:10.1038/s41598-019-46187-8
  13. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010;95(5):2038-2049. doi:10.1210/jc.2009-2724
  14. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28-38.e25. doi:10.1016/j.fertnstert.2011.09.024
  15. Lambrinoudaki I, Kazani MV, Armeni E, et al. The TyG Index as a marker of subclinical atherosclerosis and arterial stiffness in lean and overweight postmenopausal women. Heart Lung Circ. 2018;27(6):716-724. doi:10.1016/j.hlc.2017.05.142
  16. Khan SH, Sobia F, Niazi NK, Manzoor SM, Fazal N, Ahmad F. Metabolic clustering of risk factors: evaluation of Triglyceride-Glucose Index (TyG Index) for evaluation of insulin resistance. Diabetol Metab Syndr. 2018; 10:74. doi:10.1186/s13098-018-0376-8
  17. Arslan G, Karakelleoğlu G, Karadağ C. Status of a lipid accumulation product, Triglycerides/Glucose Index and Visceral Adiposity Index on cardiometabolic risk factors in young polycystic ovary syndrome patients. Ceska Gynekol. 2025;90(6):457-462. doi:10.48095/cccg2025457
  18. Wiltgen D, Benedetto IG, Mastella LS, Spritzer PM. Lipid Accumulation Product Index: a reliable marker of cardiovascular risk in polycystic ovary syndrome. Hum Reprod. 2009;24(7):1726-1731. doi:10.1093/humrep/dep072
  19. Çakır Biçer N, Ermiş AA, Baş D. The role of different methods in defining cardiometabolic risk and metabolic syndrome in women with polycystic ovary syndrome. Life (Basel). 2023;13(10):1959. doi:10.3390/life13101959
  20. Xiang S, Hua F, Chen L, Tang Y, Jiang X, Liu Z. Lipid accumulation product is related to metabolic syndrome in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2013;121(2):115-118. doi:10.1055/s-0032-1333261
  21. Demirci H, Menekse B, Ucgul E, Onaran Y, Bayram SM, Cakal E. Impact of polycystic ovary syndrome on the Atherogenic Plasma Index: a retrospective analysis. BMC Endocr Disord. 2025;25(1):185. doi:10.1186/s12902-025-02008-w
  22. Uysal E, Tammo O, Soylemez E, Incebıyık M, Filiz D, Alci M. Significance of measuring anthropometric and atherogenic indices in patients with polycystic ovary syndrome. BMC Endocr Disord. 2024; 24(1):160. doi:10.1186/s12902-024-01701-6
  23. Seo MW, Cho W, Kim JY. The Single Point Insulin Sensitivity Estimator (SPISE) Index as a predictor of metabolic syndrome in Korean adults. Obes Res Clin Pract. 2023;17(3):198-202. doi:10.1016/j.orcp.2023.05.001
  24. Welt CK, Gudmundsson JA, Arason G, et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab. 2006;91(12):4842-4848. doi:10.1210/jc.2006-1327
  25. Wen X, Wang L, Bai E. Metabolic characteristics of different phenotypes in reproductive-aged women with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2024;15:1370578. doi:10.3389/fendo.2024.1370578
  26. Pililis S, Lampsas S, Kountouri A, et al. The cardiometabolic risk in women with polycystic ovarian syndrome (PCOS): from pathophysiology to diagnosis and treatment. Medicina (Kaunas). 2024;60(10):1656. doi:10.3390/medicina60101656
  27. Barchetta I, Dule S, Bertoccini L, et al. The Single-Point Insulin Sensitivity Estimator (SPISE) Index is a strong predictor of abnormal glucose metabolism in overweight/obese children: a long-term follow-up study. J Endocrinol Invest. 2022;45(1):43-51. doi:10.1007/s40618-021-01612-6
  28. Bil E, Dilbaz B, Cirik DA, Ozelci R, Ozkaya E, Dilbaz S. Metabolic syndrome and metabolic risk profile according to polycystic ovary syndrome phenotype. J Obstet Gynaecol Res. 2016;42(7):837-843. doi:10.1111/jog.12985
  29. Bahadur A, Verma N, Mundhra R, et al. Correlation of homeostatic model assessment-insulin resistance, anti-Mullerian hormone, and BMI in the characterization of polycystic ovary syndrome. Cureus. 2021;13(6):e16047. doi:10.7759/cureus.16047
  30. Saei Ghare Naz M, Mousavi M, Mahboobifard F, Niknam A, Ramezani Tehrani F. A meta-analysis of observational studies on prolactin levels in women with polycystic ovary syndrome. Diagnostics (Basel). 2022; 12(12):2924. doi:10.3390/diagnostics12122924
  31. Yanachkova V, Stankova T. Abnormally increased prolactin levels in women with polycystic ovarian syndrome are associated with risk of obesity, insulin resistance and prediabetes. Int J Mol Sci. 2025;26(9):4239. doi:10.3390/ijms26094239
  32. Chan JL, Masini I, Pisarska MD. Polyendocrine metabolic ovarian syndrome (PMOS)/polycystic ovary syndrome (PCOS): current and future trends. J Clin Invest. 2026;136(12):e202824. doi:10.1172/JCI202824